SCHEDULE: Great Point Partners Reports 9.99% Stake in Scynexis

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay, M.D. and Ms. Lillian Nordahl, has reported beneficial ownership of 9.99% of Scynexis, Inc.'s common stock as of March 31, 2026.

Summary

• Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl have jointly filed a Schedule 13G, indicating beneficial ownership of 7,978,713 shares of Scynexis, Inc. common stock.
• This holding represents 9.99% of the class of securities outstanding as of March 31, 2026.
• The filing is made under Rule 13d-1(b) and signifies that the securities were not acquired for the purpose of influencing or changing the control of the issuer.
• The reporting persons are identified as an investment adviser (Great Point Partners, LLC) and individuals with investment power (Dr. Jay and Ms. Nordahl).
• The total number of outstanding shares used for calculating the percentage ownership is 79,866,999, which includes shares outstanding after a private placement and shares issuable upon exercise of warrants.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral; it's a standard disclosure of significant passive ownership and does not inherently indicate positive or negative performance for the company itself.

Positives

• Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl have disclosed a significant ownership stake of 9.99% in Scynexis, Inc.
• The joint filing indicates a coordinated investment strategy by the reporting persons.
• The reporting persons are eligible to file as investment advisers and individuals with investment power, suggesting a professional investment approach.

Negatives

• The filing does not contain specific financial performance data for Scynexis, Inc., making it difficult to assess the company's current financial health.
• The filing is a Schedule 13G, which is typically filed by passive investors, suggesting no intent to influence control, which might limit potential strategic impact from this holder.

Risks

• The Beneficial Ownership Cap restricts the exercise of warrants, limiting the potential increase in ownership beyond 9.99% and thus capping the reporting persons' direct influence through warrant exercise.
• The filing does not detail specific risks related to Scynexis, Inc.'s operations or market position, as it is a disclosure of ownership rather than a company-issued risk assessment.

Future Outlook

The filing does not contain forward-looking statements or guidance from Scynexis, Inc. It solely reports the ownership status of Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl.

Industry Context

StockSavvy.ai notes that a Schedule 13G filing by a significant investment firm like Great Point Partners, LLC, reporting a stake just under the 10% threshold, is common in the biotechnology and pharmaceutical sectors where substantial capital is often required for development and regulatory approval. Such filings can signal investor confidence or a strategic position ahead of potential future developments.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding a significant institutional investor's stake, which may influence market perception.
• Management: The reporting persons' passive investment approach suggests they are not seeking to exert control over management decisions at this time.

Next Steps

• The reporting persons will continue to monitor their investment in Scynexis, Inc.
• Future filings may be required if ownership levels change significantly or if the intent shifts from passive investment.

Key Dates

Keywords

Scynexis, Schedule 13G, Great Point Partners, Beneficial Ownership, Investment Adviser, Common Stock, Warrants, Ownership Stake